Core Viewpoint - WuXi Biologics has successfully completed pilot-scale end-to-end fully automated continuous production using its WuXiUP™ platform, enhancing efficiency and flexibility in biopharmaceutical development and commercialization [1] Group 1: Company Developments - WuXi Biologics' stock rose over 3% during trading, currently at HKD 31.54 with a trading volume of HKD 836 million [1] - The WuXiUP™ platform operates continuously 24/7, significantly reducing manual operations and lowering product quality risks while improving production efficiency [1] Group 2: Technological Advancements - The upstream continuous cell culture process achieves a total yield of over 110 g/L in 24 days, with a maximum daily output of 7.6 g/L, placing it at a leading level among similar processes [1] - The platform incorporates a two-step efficient membrane chromatography technology, which enhances mass transfer speed and achieves a 5-10 times increase in capacity compared to traditional resin fillers [1]